Related Experiment Video
Updated: May 7, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
FIT4Safety: recommendations in the diabetes care setting
Debra Adams1, Su Down, Debbie Hicks
1Independent Consultant Advisor/Head of Infection Prevention and Control (Midlands and East) at NHS Trust Development Authority.
British Journal of Nursing (Mark Allen Publishing)
|September 27, 2013
Summary
Sharps injuries are a significant risk in diabetes care. The FIT4Safety initiative provides recommendations to enhance safety practices and prevent injuries from sharps in the UK and Ireland.
Area of Science:
- Healthcare Safety
- Public Health
- Diabetes Management
Background:
- Sharps injuries present a substantial risk to healthcare professionals, patients, and ancillary staff.
- The FIT4Safety initiative was established to address and mitigate these risks specifically within the diabetes care setting.
Purpose of the Study:
- To introduce the FIT4Safety initiative and its core objectives.
- To present key recommendations for improving sharps safety in diabetes care.
- To highlight the importance of safety protocols in managing diabetes.
Main Methods:
- Review of the formation and aims of the FIT4Safety initiative.
- Analysis of the "Injection Safety in UK and Ireland: Safety of Sharps in Diabetes Recommendations" document.
- Discussion of relevant legislative frameworks, including EU Directive 2010/32 and UK's Health and Safety (Sharp Instruments in Healthcare) Regulations 2013.
Main Results:
- The FIT4Safety initiative aims to promote best practices for sharps safety in diabetes care.
- Comprehensive recommendations have been developed for stakeholders involved in diabetes care.
- The initiative emphasizes adherence to EU and UK regulations for sharps injury prevention.
Conclusions:
- Implementing FIT4Safety recommendations is crucial for reducing sharps injuries in diabetes care.
- Collaboration and adherence to guidelines are essential for ensuring a safe healthcare environment.
- The initiative provides a vital resource for enhancing safety standards in diabetes management.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:14SBAR II: Application of SBAR
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...